Loading
companiesCompany
Active Biotech
Active Biotech is a Swedish immunomodulator company whose tasquinimod reached phase 3 in prostate cancer without success and is now tested in myeloma.
Also called: Active Biotech AB
Overview
Active Biotech, founded in Lund in 1984 and listed in Stockholm, develops immunomodulatory small molecules. Tasquinimod, an oral S100A9 inhibitor, was taken through phase 3 in metastatic castration-resistant prostate cancer with Ipsen; it slowed radiographic progression but did not extend survival, and the programme has since moved to multiple myeloma and myelofibrosis. Its laquinimod programme sits in autoimmune disease. ClinicalTrials.gov lists Active Biotech as lead sponsor of phase 3 cancer trials.
Headquarters
Lund, SE
Scorecard
All companies#474of 1244 companies, score 5
- modalities +2
- registry trials +6
- failures -3
0 approved, 0 in phase 3, 0 earlier, 0 targets, 8 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Founded
1984
Withdrawnsmall molecule
An oral drug aimed at the tissue around the tumour rather than the cancer cells. It held the cancer back on scans and, if anything, shortened life.
Similar pages
- CompanyJW Pharmaceutical
Shares Pivotal (registrational) trial, Clinical trial, Multiple myeloma.
- CompanyForesee Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Prostate cancer.
- CompanyOakwood Laboratories
Shares Pivotal (registrational) trial, Clinical trial, Prostate cancer.
- CompanyAngiocrine Bioscience
Shares Pivotal (registrational) trial, Clinical trial, Multiple myeloma.
- CompanyCartesian Therapeutics
Shares Pivotal (registrational) trial, Clinical trial, Multiple myeloma.
- CompanyIonis Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Prostate cancer.
- CompanyPregLem
- CompanySorrento Therapeutics
Shares Pivotal (registrational) trial, Clinical trial, Multiple myeloma, Prostate cancer.
cancers
drugs
Withdrawnsmall molecule